Designing Immunotherapy Trials with Appropriate Endpoints

Introduction to Endpoints in Immunotherapy

Endpoints are the cornerstone of any clinical trial, providing the objective measures by which the efficacy and safety of a treatment are assessed. In immunotherapy clinical trials, endpoint selection is more complex than in traditional oncology due to unique response patterns, such as pseudoprogression and delayed clinical benefit. As a result, conventional criteria like RECIST v1.1 may not fully capture the therapeutic effect of immune checkpoint inhibitors, cancer vaccines, or adoptive cell therapies.

Understanding and implementing the right endpoints ensures that trials accurately measure true patient benefit, facilitates regulatory approval, and supports real-world adoption. Regulatory agencies such as the FDA and EMA emphasize endpoint selection that is clinically meaningful and scientifically justified.

Primary Endpoints in Immunotherapy Trials

Primary endpoints are the main outcomes upon which the success or failure of a trial is judged. For immunotherapy, common primary endpoints include:

• Overall Survival (OS): Considered the gold standard, OS measures the time from randomization to death from any cause. It is objective, unambiguous, and clinically meaningful.
• Progression-Free Survival (PFS): Time from randomization to disease progression or death. In immunotherapy, PFS may underestimate benefit due to delayed responses.
• Objective Response Rate (ORR): The proportion of patients with tumor size reduction of a predefined amount, based on criteria such as RECIST or immune-related RECIST (irRECIST).

OS is often preferred in Phase III trials, while ORR and PFS may be more suitable for early-phase studies to quickly assess efficacy signals.

Immune-Related Response Criteria

Traditional RECIST criteria may categorize patients with initial tumor enlargement followed by regression as having progressive disease, despite eventual benefit. To address this, immune-related response criteria (irRC) and immune RECIST (iRECIST) were developed. These frameworks allow for treatment beyond initial progression if the patient is clinically stable and imaging suggests potential delayed response.

For example, in melanoma trials with PD-1 inhibitors, up to 10% of patients classified as progressive by RECIST were later found to have durable responses under irRC evaluation.

Secondary and Exploratory Endpoints

Secondary endpoints provide additional context for interpreting trial results. These may include:

• Duration of Response (DoR): Time from initial response until progression.
• Quality of Life (QoL): Patient-reported outcomes using validated instruments like EORTC QLQ-C30.
• Immune Biomarkers: Changes in PD-L1 expression, T-cell repertoire, cytokine profiles, or ctDNA levels.

Exploratory endpoints often focus on translational research, such as identifying predictive biomarkers or immune signatures that correlate with clinical outcomes.

Regulatory Expectations for Endpoint Selection

Regulatory agencies expect endpoint selection to be justified by the mechanism of action of the therapy and the disease context. For accelerated approvals, surrogate endpoints like ORR must be “reasonably likely” to predict clinical benefit. Confirmatory trials are typically required to validate OS benefit.

The ICH E9 guideline provides statistical principles for clinical trials, emphasizing pre-specification of endpoints, clear definitions, and appropriate statistical methods to control type I error.

Case Study: KEYNOTE-006 in Advanced Melanoma

In the KEYNOTE-006 trial evaluating pembrolizumab in advanced melanoma, the primary endpoints were OS and PFS, while secondary endpoints included ORR, DoR, and safety. Notably, OS benefit was observed despite a plateau in PFS, highlighting the need to consider long-term survival as a primary measure in immunotherapy.

This trial also incorporated QoL measures, demonstrating that patients receiving pembrolizumab maintained or improved their quality of life compared to chemotherapy.

Operationalizing Endpoint Measurement

Accurate endpoint assessment requires standardized imaging schedules, consistent use of validated criteria, and centralized review of radiologic data. Immune-adapted designs may require confirmatory scans several weeks after initial progression to distinguish pseudoprogression from true progression.

Electronic patient-reported outcome (ePRO) platforms can facilitate real-time QoL data capture, improving trial efficiency and data completeness.

Conclusion

Choosing the right endpoints for immunotherapy trials is both an art and a science, balancing scientific rigor, regulatory expectations, and patient-centered outcomes. As immunotherapy continues to evolve, endpoints must adapt to capture its unique clinical benefits, ensuring that trial results translate into meaningful improvements in patient care.

Future directions may include composite endpoints that integrate survival, biomarker, and QoL data, providing a more holistic measure of benefit in oncology clinical trials.